Drug Type Small molecule drug |
Synonyms Tandutinib (USAN/INN), 坦度替尼, CT-53518 + [6] |
Mechanism FLT3 inhibitors(Tyrosine-protein kinase receptor FLT3 inhibitors), PDGFRα inhibitors(Platelet-derived growth factor receptor alpha inhibitors), PDGFRβ inhibitors(Platelet-derived growth factor receptor beta inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC31H42N6O4 |
InChIKeyUXXQOJXBIDBUAC-UHFFFAOYSA-N |
CAS Registry387867-13-2 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute Myeloid Leukemia | Phase 2 | - | 27 Feb 2006 | |
Glioblastoma | Phase 2 | US | - | |
Renal Cell Carcinoma | Phase 2 | - | - | |
Glioblastoma Multiforme | Phase 1 | - | 01 Jun 2009 | |
Myelodysplastic Syndromes | Phase 1 | US | 01 May 2002 |
Phase 2 | 10 | laboratory biomarker analysis+tandutinib | pmrwzjiafc(zmycchdqnu) = rsvuzjcpol nnlfytrssb (wlxsafhdpp, ljhsuqnule - aivygtqyug) View more | - | 04 Feb 2015 | ||
Phase 2 | 18 | hnhlkaafoi(pbarlnkgiq) = paserertgn czuwjmrlbg (bwpwvmoedi ) | - | 01 Oct 2011 | |||
Phase 2 | 18 | iomqhlsoyf(zhwjjggsxr) = rhvjoakefi pgpuxvlpcr (snhdkthjor, iekgmctzoi - oqpanndisb) View more | - | 07 Jun 2011 |